Search Browse Earnings

SELLAS Life Sciences Group, Inc. — SlamSEC

SELLAS Life Sciences Group, Inc.

Nasdaq:SLS

Pharmaceutical Preparations·NEW YORK, NY

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

Revenue

$1.0M

-86.8% YoY

FY 2023

Adj. EBITDA

-$37.9M

-3786.6% margin

FY 2024

Net Income

-$37.3M

-3734.0% margin

FY 2024

EPS (Diluted)

-$1.34

FY 2024

Stock Price

$5.82

-2.3%

2026-03-10

52W Range

$0.95 – $6.14

P/E Ratio

-4.3x

Market Cap

$829.0M

Cash

$2.5M

FY 2024

Total Debt

$2.6M

FY 2018

Net Debt

$81,000

FY 2018

Enterprise Value

$829.1M

Debt / EBITDA

-0.0x

FY 2023

EV / EBITDA

-21.9x

Employees

—

CFO

Burns John Thomas